Permanent breast seed implant dosimetry quality assurance.
OBJECTIVE
A permanent breast seed implant is a novel method of accelerated partial breast irradiation for women with early-stage breast cancer. This article presents pre- and post-implant dosimetric data, relates these data to clinical outcomes, and makes recommendations for those interested in starting a program.


METHODS
A total of 95 consecutive patients were accrued into one of three clinical trials after breast-conserving surgery: a Phase I/II trial (67 patients with infiltrating ductal carcinoma); a Phase II registry trial (25 patients with infiltrating ductal carcinoma); or a multi-center Phase II trial for patients with ductal carcinoma in situ (3 patients). Contouring of the planning target volume (PTV) was done on a Pinnacle workstation and dosimetry calculations, including dose-volume histograms, were done using a Variseed planning computer.


RESULTS
The mean pre-implant PTV coverage for the V(90), V(100), V(150), and V(200) were as follows: 98.8% ± 1.2% (range, 94.5-100%); 97.3% ± 2.1% (range, 90.3-99.9%), 68.8% ± 14.3% (range, 32.7-91.5%); and 27.8% ± 8.6% (range, 15.1-62.3%). The effect of seed motion was characterized by post-implant dosimetry performed immediately after the implantation (same day) and at 2 months after the implantation. The mean V(100) changed from 85.6% to 88.4% (p = 0.004) and the mean V(200) changed from 36.2% to 48.3% (p < 0.001). Skin toxicity was associated with maximum skin dose (p = 0.014).


CONCLUSIONS
Preplanning dosimetry should aim for a V(90) of approximately 100%, a V(100) between 95% and 100%, and a V(200) between 20% and 30%, as these numbers are associated with no local recurrences to date and good patient tolerance. In general, the target volume coverage improved over the duration of the seed therapy. The maximum skin dose, defined as the average dose over the hottest 1 × 1-cm(2) surface area, should be limited to 90% of the prescription dose to minimize delayed skin toxicity.
Department of Medical Physics, Sunnybrook Health Sciences Center, Toronto, ON, Canada. Brian.Keller@sunnybrook.ca
Brian M
BM
Keller
Ananth
A
Ravi
Raxa
R
Sankreacha
Jean-Philippe
JP
Pignol
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000295:instrumentation / Q000379:methods* / Q000592:standards; D001940:Breast / Q000528:radiation effects; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D018270:Carcinoma, Ductal, Breast / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010165:Palladium / Q000627:therapeutic use; D011785:Quality Assurance, Health Care / Q000379:methods*; D011855:Radiodermatitis / Q000473:pathology; D011859:Radiography; D011868:Radioisotopes / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods
D011868:Radioisotopes; D010165:Palladium